Literature DB >> 4031501

Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48.

J J Schlesinger, M W Brandriss, E E Walsh.   

Abstract

The protective capacity of antiviral antibodies has generally been considered to depend on their interactions with structural components of the virion. Here we report protection against lethal 17D yellow fever virus (YF) encephalitis of mice by passive administration of nonneutralizing monoclonal antibodies to a 17D YF-specified nonstructural glycoprotein, gp48, and by active immunization with purified gp48. Among five anti-gp48 monoclonal antibodies tested, two with high titer complement-fixing (CF) activity were protective, whereas three antibodies with little or no CF activity were not. The ability of antibodies to protect correlated with their ability to promote complement-mediated cytolysis (CMC) of 51Cr-labeled 17D YF-infected mouse neuroblastoma (Neuro 2a) cells. Purified gp48, prepared from lysates of 17D YF-infected Vero cells by immunoaffinity chromatography, was shown to bear both YF type-specific and flavivirus group-reactive determinants in a solid phase radioimmunoassay. Immunization of mice with purified gp48 resulted in solid protection in the absence of detectable anti-virion antibody, measured by neutralization and radioimmunoprecipitation assays. The results are consistent with plasma membrane expression of gp48 and susceptibility of 17D YF-infected neural cells to CMC, a possible mechanism of host defense in 17D YF encephalitis. Protection provided by immunization with gp48, which bears a group-reactive determinant and is highly conserved among flaviviruses, may have implications in regard to flavivirus vaccine design.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031501

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  80 in total

1.  Characterization of a siberian virus isolated from a patient with progressive chronic tick-borne encephalitis.

Authors:  T S Gritsun; T V Frolova; A I Zhankov; M Armesto; S L Turner; M P Frolova; V V Pogodina; V A Lashkevich; E A Gould
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Amelioration of established Sendai viral pneumonia in the nude mouse using a monoclonal antibody to the virus fusion protein.

Authors:  P Carthew; J Riley; D Dinsdale
Journal:  Br J Exp Pathol       Date:  1989-12

3.  Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Authors:  A V Timofeev; V M Butenko; J R Stephenson
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

4.  A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition.

Authors:  Soonjeon Youn; Hyelim Cho; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

5.  Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a.

Authors:  B Falgout; R Chanock; C J Lai
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Hemagglutinin-esterase-specific monoclonal antibodies alter the neuropathogenicity of mouse hepatitis virus.

Authors:  K Yokomori; S C Baker; S A Stohlman; M M Lai
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

7.  Flavivirus nonstructural protein NS1: complementary surprises.

Authors:  Jacob J Schlesinger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-04       Impact factor: 11.205

8.  Expression of the structural proteins of dengue 2 virus and yellow fever virus by recombinant vaccinia viruses.

Authors:  Y S Hahn; E M Lenches; R Galler; C M Rice; J Dalrymple; J H Strauss
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

9.  Expression of the NS1 gene of dengue virus type 2 using vaccinia virus. Dimerisation of the NS1 glycoprotein.

Authors:  C R Parrish; W S Woo; P J Wright
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

10.  Role of CD8+ T cells in control of West Nile virus infection.

Authors:  Bimmi Shrestha; Michael S Diamond
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.